Womble Bond Dickinson (US)

Womble Bond Dickinson (US) is a full-service, transatlantic AmLaw 100 law firm, operating with 32 U.S. offices and 8 in the U.K., totaling 40 locations and housing over 1,100 attorneys globally.. While its U.S. headquarters are in Winston-Salem, North Carolina, the firm maintains a significant presence across key litigation venues including Delaware, California, and Texas. The firm is recognized for its broad legal offerings, with its U.S. entity alone having 482 lawyers recognized by Best Lawyers across 109 practice areas.

The firm's Intellectual Property Litigation team is adept at protecting and defending clients' interests across a diverse range of technology areas. Their expertise spans electrical, chemical, pharmaceutical, computer software, mechanical, electromechanical, and biotech arts. Notable engagements reflect this breadth, including representing Intent IQ LLC in ad-tech litigation, Mundra Solar in solar technology disputes, Halozyme, Inc. in pharmaceutical/biotech cases, Veloxis Pharmaceuticals, Inc. in ANDA litigation, and defending Therabody Inc. in matters involving percussive massage device technology. Womble Bond Dickinson actively litigates patent infringement, copyright, trademark, and trade secret disputes, including related antitrust or unfair competition claims.

Womble Bond Dickinson demonstrates a balanced, but slightly plaintiff-leaning, approach to patent litigation, having appeared in four plaintiff-side cases and two defendant-side cases in its tracked matters. The firm's IP Litigation team represents clients both in asserting claims against infringers and in defending against allegations of infringement. For example, the firm represents Halozyme, Inc., which secured a preliminary injunction against Merck's Keytruda SC in Germany in late 2025 regarding a key patent. However, this momentum was partially offset by a U.S. Patent Trial and Appeal Board (PTAB) decision in May 2026 invalidating one of Halozyme's core patents challenged by Merck, which weakened Halozyme's position in related U.S. infringement proceedings. In another instance, Womble Bond Dickinson defended Therabody Inc. in a patent infringement suit filed by Hyperice IP Subco LLC, which was administratively closed and consolidated with related cases for pretrial proceedings in late 2024. The firm's involvement for Mundra Solar PV Limited against First Solar, Inc. in the District of Delaware is currently stayed pending an International Trade Commission determination.

The firm maintains a notable Post-Grant Review (PGR) and Inter Partes Review (IPR) practice, with its attorneys regularly litigating before the U.S. Patent and Trademark Office (USPTO). While a specific volume of IPR filings is not publicly available, the firm's website indicates extensive experience in this area. In a case involving one of their clients, Mundra Solar, IPR applications seeking to invalidate First Solar's TOPCon patents were denied by the USPTO in late 2025. Key partners in the firm's IP litigation practice include Michael McCue, Co-Leader of the Trademark, Copyright, Privacy & IP Transactions Practice Group; Thomas J. Daly, known for his 25 years of experience in patent procurement, licensing, and enforcement, particularly in medical devices and pharmaceuticals; and Jason Chu, whose practice emphasizes patent procurement, strategic planning, counseling, due diligence, and litigation across software, life sciences, and semiconductor technologies, with specific experience in PTAB and IPR proceedings.